Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.
Wischik
C
C
Old Age Psychiatry, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland, UK. cmw@taurx.com
Staff
R
R
D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015415:Biomarkers / Q000032:analysis* / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016875:tau Proteins / Q000032:analysis* / Q000378:metabolism
D015415:Biomarkers; C054369:MAPT protein, human; D016875:tau Proteins